Suppr超能文献

趋化因子受体寡聚化和变构。

Chemokine receptor oligomerization and allostery.

机构信息

Skaggs School of Pharmacy and Pharmaceutical Science, University of California, San Diego, La Jolla, California, USA.

出版信息

Prog Mol Biol Transl Sci. 2013;115:375-420. doi: 10.1016/B978-0-12-394587-7.00009-9.

Abstract

Oligomerization of chemokine receptors has been reported to influence many aspects of receptor function through allosteric communication between receptor protomers. Allosteric interactions within chemokine receptor hetero-oligomers have been shown to cause negative cooperativity in the binding of chemokines and to inhibit receptor activation in the case of some receptor pairs. Other receptor pairs can cause enhanced signaling and even activate entirely new, hetero-oligomer-specific signaling complexes and responses downstream of receptor activation. Many mechanisms contribute to these effects including direct allosteric coupling between the receptors, G protein-mediated allostery, G protein stealing, ligand sequestration, and recruitment of new intracellular proteins by exposing unique binding interfaces on the oligomerized receptors. These effects present both challenges as well as exciting opportunities for drug discovery. One of the most difficult challenges will involve determining if and when hetero-oligomers versus homomeric receptors are involved in specific disease states.

摘要

趋化因子受体的寡聚化已被报道通过受体原聚体之间的变构通讯影响受体功能的许多方面。趋化因子受体异源寡聚体内部的变构相互作用已被证明导致趋化因子结合的负协同作用,并在某些受体对的情况下抑制受体激活。其他受体对可以引起信号增强,甚至激活全新的、异源寡聚体特异性信号复合物,并在受体激活的下游引起反应。许多机制促成了这些效应,包括受体之间的直接变构偶联、G 蛋白介导的变构作用、G 蛋白窃取、配体隔离以及通过暴露寡聚化受体上独特的结合界面来招募新的细胞内蛋白。这些效应既带来了挑战,也为药物发现带来了令人兴奋的机会。其中最具挑战性的挑战之一将涉及确定在特定疾病状态下,是异源寡聚体还是同源受体参与。

相似文献

1
Chemokine receptor oligomerization and allostery.
Prog Mol Biol Transl Sci. 2013;115:375-420. doi: 10.1016/B978-0-12-394587-7.00009-9.
2
Chapter 10. Hetero-oligomerization of chemokine receptors.
Methods Enzymol. 2009;461:207-25. doi: 10.1016/S0076-6879(09)05410-X.
3
Hetero-oligomerization of chemokine receptors: diversity and relevance for function.
Curr Med Chem. 2013;20(20):2524-36. doi: 10.2174/09298673113209990117.
4
Chemokine receptor oligomerization: functional considerations.
Curr Opin Pharmacol. 2010 Feb;10(1):38-43. doi: 10.1016/j.coph.2009.09.004. Epub 2009 Oct 12.
5
Allosteric inhibition of g-protein coupled receptor oligomerization: strategies and challenges for drug development.
Curr Top Med Chem. 2014;14(15):1842-63. doi: 10.2174/1568026614666140901130843.
6
Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers.
Mol Pharmacol. 2006 May;69(5):1652-61. doi: 10.1124/mol.105.019414. Epub 2006 Feb 7.
7
Use of Resonance Energy Transfer Techniques for In Vivo Detection of Chemokine Receptor Oligomerization.
Methods Mol Biol. 2016;1407:341-59. doi: 10.1007/978-1-4939-3480-5_24.
8
What Do Structures Tell Us About Chemokine Receptor Function and Antagonism?
Annu Rev Biophys. 2017 May 22;46:175-198. doi: 10.1146/annurev-biophys-051013-022942.
9
Structural perspectives on chemokine receptors.
Biochem Soc Trans. 2024 Jun 26;52(3):1011-1024. doi: 10.1042/BST20230358.
10
The multilayered complexity of the chemokine receptor system.
Biochem Biophys Res Commun. 2020 Jul 23;528(2):347-358. doi: 10.1016/j.bbrc.2020.02.120. Epub 2020 Mar 5.

引用本文的文献

1
Structural insights into CXCR4 modulation and oligomerization.
Nat Struct Mol Biol. 2025 Feb;32(2):315-325. doi: 10.1038/s41594-024-01397-1. Epub 2024 Sep 23.
2
The chemokine receptor CCR5: multi-faceted hook for HIV-1.
Retrovirology. 2024 Jan 23;21(1):2. doi: 10.1186/s12977-024-00634-1.
4
Discovery and characterization of a functional scFv for CCR2 inhibition via an extracellular loop.
Int J Pharm. 2023 Feb 5;632:122547. doi: 10.1016/j.ijpharm.2022.122547. Epub 2022 Dec 24.
5
Sphingomyelin Depletion Inhibits CXCR4 Dynamics and CXCL12-Mediated Directed Cell Migration in Human T Cells.
Front Immunol. 2022 Jul 12;13:925559. doi: 10.3389/fimmu.2022.925559. eCollection 2022.
6
Shifting CCR7 towards Its Monomeric Form Augments CCL19 Binding and Uptake.
Cells. 2022 Apr 25;11(9):1444. doi: 10.3390/cells11091444.
8
The Role of miRNA in Regulating the Fate of Monocytes in Health and Cancer.
Biomolecules. 2022 Jan 7;12(1):100. doi: 10.3390/biom12010100.
9
Tetraspanin Cd9b and Cxcl12a/Cxcr4b have a synergistic effect on the control of collective cell migration.
PLoS One. 2021 Nov 30;16(11):e0260372. doi: 10.1371/journal.pone.0260372. eCollection 2021.

本文引用的文献

2
EBI2 regulates CXCL13-mediated responses by heterodimerization with CXCR5.
FASEB J. 2012 Dec;26(12):4841-54. doi: 10.1096/fj.12-208876. Epub 2012 Aug 22.
3
A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry.
Biochemistry. 2012 Sep 11;51(36):7078-86. doi: 10.1021/bi2016712. Epub 2012 Aug 29.
5
The biochemistry and biology of the atypical chemokine receptors.
Immunol Lett. 2012 Jul 30;145(1-2):30-8. doi: 10.1016/j.imlet.2012.04.004.
6
Chemokine receptor oligomerization: a further step toward chemokine function.
Immunol Lett. 2012 Jul 30;145(1-2):23-9. doi: 10.1016/j.imlet.2012.04.012.
8
Characterization of the homodimerization interface and functional hotspots of the CXCR4 chemokine receptor.
Proteins. 2012 Aug;80(8):1919-28. doi: 10.1002/prot.24099. Epub 2012 May 25.
9
Identification and profiling of novel α1A-adrenoceptor-CXC chemokine receptor 2 heteromer.
J Biol Chem. 2012 Apr 13;287(16):12952-65. doi: 10.1074/jbc.M111.322834. Epub 2012 Feb 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验